Genmab wins biotechnology's Helix Award 2004

28-Feb-2005

Genmab A/S announced it has won the James D. Watson Helix Award in the international category. The Helix Award honors biotechnology companies that display leadership in three areas: scientific innovation, company growth and corporate citizenship. Winners are selected by peer vote and the award was presented at the BIO CEO and Investor Conference in New York.

Genmab was honored for its significant advances during 2004 that included the presentation of positive data from all five of its clinical programs: Phase II proof of concept data for two products, HuMax-CD4 and the Amgen partnered AMG-714, and promising Phase I/II data for HuMax-CD20, HuMax-EGFr and HuMax-Inflam. Genmab also received Fast Track designations for HuMax-CD4 and HuMax-CD20 from the FDA and obtained two Orphan Drug designations. In the financial area, the company raised a total of approximately DKK 542 million (approximately US$100 million), primarily through a successful follow on offering, and the company's stock price appreciated by 96% during the year.

The award was presented by the Long Island Life Sciences Initiative and is jointly sponsored by the Biotechnology Industry Organization, Stony Brook University and The Center for Biotechnology.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances